home / stock / anab / anab message board
Subject | By | Source | When |
---|---|---|---|
HighPeaks, The NY Times article was | gfp927z | investorshub | 06/10/2022 4:40:20 PM |
Thanks TP. Yeah this has the potential to | HighPeaks | investorshub | 06/10/2022 3:36:11 PM |
Tremendous find HighPeaks. .You have been early on | tedpeele | investorshub | 06/10/2022 5:30:31 AM |
According to this link ANAB gets 8-25% royalties | HighPeaks | investorshub | 06/08/2022 7:33:46 PM |
$ANAB / #Anaptysbio Spikes After Drug Designation | TFMG | investorshub | 07/09/2020 1:28:42 AM |
RSI @ 16. laughable. Zacks has positive take. https://finance.yahoo.com/news/ana | LoveItInBishop | investorshub | 11/18/2019 4:46:05 AM |
* * $ANAB Video Chart 11-13-19 * * | ClayTrader | investorshub | 11/13/2019 8:58:42 PM |
* * $ANAB Video Chart 11-08-19 * * | ClayTrader | investorshub | 11/08/2019 10:08:21 PM |
LOL! Twitter PnD. Buyer beware. | waterchaser | investorshub | 11/08/2019 9:26:03 PM |
Once the real bounce starts it will be fast.... | 420man | investorshub | 11/08/2019 6:25:07 PM |
$10 to da moon :-) | Crazy Money | investorshub | 11/08/2019 5:56:42 PM |
This will bounce..... 15 AH | 420man | investorshub | 11/08/2019 5:44:12 PM |
trying to bounce back over $11, hoping for more | RJ Trotts | investorshub | 11/08/2019 3:08:17 PM |
Ouch - | TaxiCaT | investorshub | 11/08/2019 2:23:32 PM |
Nothing happen here? | celle | investorshub | 05/25/2019 8:20:04 AM |
This stock is making noise! Bought in Sept | manny371 | investorshub | 12/31/2017 3:08:00 PM |
News, Short Squeeze, Breakout and More Instantly...
2024-05-10 18:15:02 ET Wells Fargo analyst issues BUY recommendation for ANAB on May 10, 2024 05:01PM ET. The previous analyst recommendation was Buy. ANAB was trading at $23.41 at issue of the analyst recommendation. The overall analyst consensus : HOLD. Current ana...
Enrollment ongoing for global Phase 2b trial to treat atopic dermatitis (AD) with ANB032, our BTLA agonist; reiterating top-line data anticipated by year-end 2024 Enrollment ongoing for global Phase 2b trial to treat rheumatoid arthritis (RA) and global Phase 2 trial to treat ulcerative colit...
All eight patients from GEMINI-1 who responded to a single intravenous (IV) imsidolimab dose and were subsequently re-randomized to monthly subcutaneous (SC) maintenance dosing of imsidolimab in GEMINI-2 through at least 24 weeks maintained clear to almost clear skin and none experienced a flare ...